Events

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 12 July, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Is A2 for you?
Presented by A2 Corporation’s Chief Scientific Officer Dr Andrew Clarke

Rarely – never? - has a food caused so much controversy. A2 Corporation does not make any health claims about its milk – it is not even really a functional food – it excludes a protein variant that appears not to be associated with certain conditions.

A2 milk is a natural variant of ordinary milk produced by a natural genetic variant of ordinary cows. The debate about the science behind A2 can be passionate; the evidence that, for some people, ordinary milk increases the symptoms of a range of intolerance type responses and neurological conditions, coupled with linkages to a reduced risk of type 1 diabetes and heart disease this may have significant implications to subsets of populations and lead to future nutigenomic applications.

A2 Corporation’s Chief Scientific Officer Dr Andrew Clarke is an alumni of the U of A’s School of Biological Sciences. Andrew completed his PhD with Prof Garth Cooper and then joined Protemix, characterizing targets of drugs in pre-clinical trials. This was followed by two years as a consultant to both biotech start-ups and potential investors before joining A2 Corporation and publically listing the company (NZX:ATM) to aid in the commercialisation of its unique technology. We are delighted to welcome Andrew as the guest speaker at this month’s forum to discuss A2’s proprietary milk and the insights gained as A2 have commercialised their product.

Beta- casein is one of the most important proteins found milk. Genetic variation results in two main forms of this protein, known as A1 and A2. Bioactives formed during the digestion of beta- casein are important in the transport of essential ions and nutrients. However, one of the products of digestion of the A1 form is a fragment known as BCM-7. This fragment has strong opioid properties and is widely believed to have the potential to interfere with the immune system in people with particular genetic susceptibilities. It has also been shown to catalyse the formation of oxidised LDL, an established risk factor in the development of arterial problems. Current research includes establishing the molecular mechanism by which BCM-7 affects cellular inflammation, which was presented to ICFSN2013 in London earlier this week (8 July).

The A2 form does not produce BCM-7. It is this small difference that gives A2 milk, containing only the A2 form of beta-casein, its selling point. With seven patents covering the supply chain from testing through to composition and use A2 has been able to produce a highly protected brand.

Between the skeptics, legal issues and ‘learning experiences’ with licensing partners A2 has not had an easy road, even by biotech standards. However, with its seven patents behind it, plus its own manufacturing plants, plus distribution in Australia, China and the UK, plus a strong and rapidly growing market share in the specialty milk sector, the future is looking positive.

You are warmly invited to join us to hear A2 Corporation’s CSO, Dr Andrew Clarke, discuss the process of successfully developing the value of A2 milk.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 14 June, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: ‘Thank You’ From All the Fish
Presented by Photonz CSO, Dr Hywel Griffiths

While not all the many claims for the ‘wonder’ molecules in the Omega-3 family have convincing evidence, few people could doubt the impact and importance they have had on the health and wellness sector. I am sure that everyone reading this is very conscious of their weekly intake of fish and/or daily fish-oil capsule. Fish, with their relatively high proportions of the longer chained omega-3’s EPA and DHA, are consider the far superior source for these compounds. Plant oils simply cannot compete.

But fish get their omega-3’s from algae – and Photonz – the company featuring at the June forum – have gone to the source. They ferment marine microalgae to produce their fermentation product PNZ0901 and, from there, high purity EPA (eicsapentaenoic acid).

Their proprietary technology owns or controls seven patent families. Importantly, it overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

The overall process also has some huge advantages. It is….

• Sustainable; does not deplete threatened fish stocks
• Scaleable
• Able to produce a consistent, reliable supply of product
• Free from heavy metals or other contaminants and pollutants associated with fish sources
• Secure and traceable.

EPA is a critical ingredient in regulated pharmaceutical products and medicinal foods addressing cardiovascular disease. The ability of Photonz to provide a high purity and reliable source of EPA that is scaleable on demand allows them to supply drug manufacturers with confidence. Given that the global cardiovascular disease market generates annual sales in excess of USD 60 billion and as such is the world's biggest pharmaceutical segment, this is not a bad thing!

You are warmly invited to join us as Photonz CSO, Dr Hywel Griffiths talks about Photonz, from idea to implementation.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:director@bioscenterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 17 May, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: It's not a frog .......
Presented by General Manager of the Riddet Insititute, Mark Ward

.. but it is a New Zealand native. The Riddet Institute is New Zealand’s Centre of Research Excellence in an area that is increasingly credited with having one of the greatest potential impacts on NZ’s economy – the area where food meets health.

General Manager of the Riddet Insititute, Mark Ward, is the guest speaker at the next Bioscience Enterprise forum. He is passionate about now being the opportunity for many disciplines to converge – nutrition, agritech, food processing and health – to position New Zealand as the food nation for the future. ‘Future foods’, incorporating functional foods, targeted ingredients and ‘I’ (personalised) - foods, will be the key vehicle for health and wellness.

Mark’s presentation will relate global trends and demand to New Zealand’s attributes and expertise.

The Riddet Institute - bringing together leading scientists from Massey, Otago and Auckland Universities as well as Plant & Food and AgResearch – plays a pivotal role in fortifying the New Zealand food industry with scientific excellence. With more than 50 scientists plus another 50 PhDs, Riddet provides world-class competency in the areas of biomaterials science and digestive physiology relating to nutrient absorption and metabolism. Riddet’s six major areas of research range from gastrointestinal biology to modeling and engineering to innovative food solutions.

Riddet works closely with the food industry, both within NZ and internationally. Their wide-range of R&D projects have involved engaging with Fonterra, ZESPRI, Beef and Lamb NZ, PepsiCo, BASF, Yashili and DSM.

Please join us to discuss Mark Ward’s vision for the future for NZ where the bioscience disciplines converge to increase the whole value chain for health and wellness.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 19 April, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: ATEED grows weed?
Presented by Brett O’Riley, Chief Executive of ATEED (Auckland Tourism, Events and Economic Development agency)

Maybe a bit of a stretch, but I do have some Omega-3s derived from hemp at home and ATEED do want to grow Auckland’s life science industry, therefore …..?

We are delighted to welcome Brett O’Riley, Chief Executive of ATEED (Auckland Tourism, Events and Economic Development agency) as the guest speaker at the next Bioscience Enterprise forum.

ATEED has the mission to improve New Zealand’s economic prosperity by leading the successful transformation of Auckland’s economy. The restructuring that ATEED undertook late last year has included the formation of the Business Attraction and Investment Team. The Life Sciences are among the team’s main targets and supporting innovation, attracting new talent and growing investment in the region are among its principle aims.

Brett has wide experience working on change and development projects in both New Zealand and internationally. His senior management positions over the past 20 years, in both private and public sectors, include his recent role as Deputy Chief Executive, Business Innovation and Investments for the Ministry of Science and Innovation.

Please join us for Brett O’Riley’s presentation on ATEED’s plans for the business growth opportunities in the Life Sciences.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:Director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 1 March, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Insights from Innate
Presented by Innate’s CSO, Dr Gill Webster and Business Development Manager Mr Peter Bradley

Innate Immunotherapeutics will be well known to many of you – as will the guest speakers at the first Bioscience Enterprise forum for 2013, Innate’s CSO, Dr Gill Webster and Business Development Manager Mr Peter Bradley.

Innate is a company characterised by passion; from the CSO through to the business manager, CEO and shareholders, the potential for their therapy to make a difference – a real difference – to the lives of their patients is a driving force.

Unfortunately, as we all know, passion is not enough. A strong business plan and funding are needed to support that passion – and strong science is needed to support the business plan. It is these factors that will be the focus of this month’s presentation.

Innate faces the additional challenge of introducing a treatment that is contrary to the traditional approach. Innate’s platform technology is a microparticle that stimulates the immune system and can also target specific cells after being modified by attaching selected modulators to its surface. It has wide potential applications from autoimmune and immune-sensitive diseases to infectious diseases to more effective vaccines.

The focus to date has been on secondary progressive multiple sclerosis (SPMS). People who have developed this form of MS experience the greatest degree of neurological disability and no longer go into remission. Current treatments available are based on immunosuppression . The serious negative side-effects of these drugs mean this treatment is very limited. Innate’s treatment is unique – it is both immune-enhancing and non-toxic. Results from both compassionate and phase 2a trials exceeded expectations, with patients reporting greatly improved cognitive as well as physical function.

Innate Immunotherapeutics Ltd is a public unlisted company with 1700 shareholders based mostly in NZ and the USA. The shareholders have raised over $40M for Innate’s research, with further support coming from NZTE, MSI, the MS Society (US) and Merck Serono. Innate is currently in the process of raising a further $10M for a phase 2b trial. It is planned that this drug will be acquired by one of the big pharma companies by 2015 in order to enter the $3B market and reach all people suffering from SPMS.

You are warmly invited to share Innate Immunotherapeutics insights to the importance of the science - business interface in a funding constrained environment.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 7th December, 2012
Time: Networking 4:00pm, Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: On The Edge
Presented by Dave Darling, CEO of Pacific Edge

On the edge of a new year, the 2012 MBioEnt students on the edge of their professional career and Pacific Edge on the edge of……..global domination?

We are delighted that Dave Darling, CEO of Pacific Edge, will be the guest speaker for the final Bioscience Enterprise forum for 2012.

Specialising in using proteomic and genomic tools to develop technologies that allow earlier detection and monitoring of cancer, Pacific Edge not only identifies reliable biomarkers but also develops novel simple-to-use tests that have high accuracy and utility and so provide significant advances in clinical practice. They also provide the analysis for these tests through a laboratory service.

With Cxbladder on the market, Cxcolorectal in the final stages of development, a test for gastric cancer and another for melanoma in pre-clinical trials, Pacific Edge is already impacting on the field of cancer diagnosis and prognosis. They currently provide a laboratory service in New Zealand and Australia and are set to expand. Pacific Edge now has a wholly-owned subsidiary in the US – a purpose-built laboratory in Hershey, Pennsylvania with the capacity to carry out 260,000 tests for bladder cancer per year. This facility, due to be granted regulatory approval by early 2013, is intended to provide a better and more cost-effective choice to the 17,000 urologists in the US who currently spend $1 billion annually identifying bladder cancer in their patients. The fact that this facility was finished both on-schedule and within budget is certainly a positive start!

Dave joined Pacific Edge in 2003 bringing a wealth of experience in developing start-ups and early stage technologies. He has led Pacific Edge from its discovery stage through to commercialisation. While the US lab ‘going–live’ commercially in 2013 will no doubt be a wonderful 10th birthday present there have been many challenges along the way. This presentation will provide insight to some of those (sometimes unexpected) challenges.

Please join us to celebrate the end of the year and to hear CEO Dave Darling talk about Pacific Edge’s road to success.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to the nutraceutical industry for a networking function at the University of Auckland

Date: Tuesday 4th December 2012
Time: 4:30pm – 6.00pm networking forum including tours of the facilities
Venue: Reception lounge, School of Biological Sciences, Thomas Building, 3A Symonds St, Auckland.
Parking: Under the Owen G Glenn Building, 12 Grafton Rd

Food and health is one of the thematic priority areas for the University of Auckland and we would like to invite you to this networking event where you will:

  • Increase your network with other players in the nutraceutical sector (company and University staff) over drinks and nibbles.
  • Learn how you can support your products with cutting-edge science by accessing the University’s wide-ranging expertise, advanced facilities for research and development, analytical systems, bioactivity and bioavailability assays, and human clinical trials for new functional foods.
  • Join us on a tour around through the facilities of the School of Biological Sciences and the Institute for Innovation in Biotechnology.
  • Understand through a brief presentation how you can join this vibrant environment and partner with the University through contract research, secondments of company staff and/or co-location of an R&D team.

Who will attend?

Representatives from companies developing and manufacturing nutraceutical products, functional foods, supplements and/or ingredients, and representatives from public sector organisations engaged in this industry, are cordially invited to this event. University staff active in this sector and wishing to engage with the industry are kindly invited to attend.

Where is it?

Institute for Innovation in Biotechnology where companies can second staff or co-locate an R&D team to gain full access to the expertise, specialist facilities and hi-tech equipment in the University’s School of Biological Sciences. Opportunities exist to collaborate with relevant academic groups University-wide, including human nutrition trials and clinical trials.

All welcome. RSVPs to Joerg Kistler, Director IIB, for organisational purposes would be greatly appreciated. Please email your name and company name as you would like it to appear on the name tags to j.kistler@auckland.ac.nz.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 19th October, 2012
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Beyond the ‘Three B’s’(x2?)
Presented by Wayne Leech, Head of Centre for Innovation & Development, Bayer NZ

We know that Bayer Bought Bomac, but did that give the Bomac owners the Boat, the Bach and the BMW? And what has happened to Bomac? Our guest speaker for the October forum is Wayne Leech, Head of Centre for Innovation & Development, Bayer NZ and former CEO of Bomac. He will provide insight to the former three B’s – no promises about the latter – from his perspective of running a New Zealand company that is now an important element of a multinational corporate.

Bayer’s acquisition of Bomac in 2011 brought together two very different business cultures. It was also a striking example of the value of animal health to NZ’s bio industry. The acquisition process itself is of great interest. While Bomac was NZ’s largest privately owned animal healthcare company with 200 staff and 290 products being sold in over 60 countries, it was dwarfed by Bayer. Bayer was a multinational with over 108,000 staff, generating a revenue of 31.2 billion Euros. How was Bomac valued and what is its new role?

Please join us to hear Wayne Leech tell the Bomac to Bayer story and provide insight to the role and operation of this Bayer NZ company.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 14th September, 2012
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Bowling You Over
Presented by David Anstice, Business Development Manager for the Food Bowl and Sector Specialist, Food and Beverage, with ATEED

The Food Bowl at Manukau, with its 2000 square meters of space and processing equipment aimed at supporting companies moving from lab-bench ‘R’ and into the ‘D’ phase, should be of great interest to the bioscience industry. Already utilised by Plant & Food and several SME’s in this sector, this is an exciting entity.

The Food Bowl is a model of infrastructure, skilled support and facilities that encourages strategic sector clustering.

It is already identified as an iconic company/organisation that will be included in the new Advanced Technology Institute (ATI).

Several millions of dollars of state-of-the-art high tech equipment allows for innovative approaches throughout the processing of many forms of food and beverage produced for a variety of functions.

Confidentiality for the companies utilising the Food Bowl is assured by the presence of 4 totally independent processing suites, complemented by private carparking. Each suite is available for as short a time as one day.

Flexibility and wide ranging capability is assured by complementing the several large fixed pieces of high tech equipment, such as the High Pressure Pasteurization machine, with over 200 pieces of mobile ancillary pieces of equipment.

GMP accreditation allows companies in the health space to produce product for clinical trials.

FSP (Food Safety Programme) and RMP (Risk Management Programme) registration allows companies to assess the issues associated with scale up of production under regulated conditions. Together with the ability to produce small scale commercial quantities, companies have the potential to significantly increase their business development options.

David Anstice, Business Development Manager for the Food Bowl and Sector Specialist, Food and Beverage, with ATEED will be our guest speaker at this month’s forum.

You are warmly invited to take the opportunity to be ‘bowled over’ as David explains how the Food Bowl is increasing NZ’s capability and productivity in the F&B sector and to consider the possibilities this model has for the wider bioscience industry.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 17th August 2012
Time: Presentation – 4.30 pm.
Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.

NZTE – At Your Service

You may have noticed the odd change or two taking place within/between / around the government departments and organisations that have traditionally supported the bioscience industry? New Zealand Trade & Enterprise has not been spared from these events and is now operating under quite a new ‘look’. The industry sectors are gone and companies now have the opportunity to engage under programmes and projects. We thought it would be timely to become better aquainted with the possibilities.

Our guest speaker, Hans Frauenlob, is NZTE’s General Manager, Products and Services. In this role he leads the design and delivery of the Beachheads Programme which many of you will be familiar with. You may not be so familiar with two other programmes that NZTE have identified as being strategically important to building industry capability that Hans also leads – Better By Design and Lean Business.

Hans’ presentation will look at how NZTE delivers the current government policy and NZTE’s relationship with the newly formed MoBIE and ATI. As well as the programmes he leads,Hans will also consider other services offered one-on-one to companies such research into market intelligence. He will also describe the significance of the eight High Impact programmes such as Health, Agribusiness and China and how they support the life science industry.

You are warmly invited to take the opportunity to join us and learn more about how to access NZTE’s products and services from General Manager Hans Frauenlob.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

Public car parking is available nearby under the U of A’s Business School, the Owen G Glenn Building, in Grafton Rd. (see attached map). There is also limited parking available in Princes St.